key: cord-0955044-3y7v80pn
authors: Levine, Irving; Swaminath, Arun; Roitman, Isabel; Sultan, Keith
title: COVID-19 Vaccination and IBD: Desired antibody responses, future directions, and a note of caution
date: 2021-05-18
journal: Gastroenterology
DOI: 10.1053/j.gastro.2021.05.030
sha: c74017fcf3d222741374f8ba98840d945fcdf602
doc_id: 955044
cord_uid: 3y7v80pn

nan

infliximab-treated patients and 86% (6/7) vedolizumab-treated patients seroconverting. While our sample size is also small, the additional numbers, expansion to patients not on biologic therapy, and the inclusion of a commercially available ELISA assay add further support to Wong's and Kennedy's findings. Still, much more data will be needed to determine the true effectiveness of SARS-CoV-2 vaccination in this high-risk population. Notably, Kennedy also observed the lower vaccine response rates following a single dose of vaccine in the infliximab treated patients as well as those with immunomodulator use. Coupling this with reports demonstrating that combination therapy with TNF antagonists and steroid or thiopurines is associated with severe COVID-19 among patients with IBD suggests that specific vaccine protocols (or requirement for confirmation of a satisfactory neutralizing antibody response) may need to be developed for this highest risk population. 3 Also, as information accumulates on the initial antibody response post vaccination, longer term follow-up will be needed to track the durability of antibody response, as well as responses to newer vaccines both in the IBD and general population.

There is one critical point to note, particularly at a time where many are still waiting for their first SARS-CoV-2 vaccine. Previous studies have demonstrated that patients with IBD have lower serologic response rates to HBV 4 , pneumococcal 5 , and H1N1-influenza vaccination 6 , with IBD clinicians encouraged to check serologies and re-vaccinate those with low or absent antibody responses 7 . Though we suspect that time and vaccine availability will lead to the same approach with regards to SARS-CoV-2, there is currently no consensus/recommendations on re-vaccination following a negative serologic response. As post vaccine testing becomes

Serological response to mRNA COVID-19 vaccines in IBD patients receiving biological therapies

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Effect of IBD medications on COVID-19 outcomes: results from an international registry

Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls

Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study

Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease

A practical guide to vaccinating the inflammatory bowel disease patient